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Abstract
Crohn’s disease (CD) is a chronic inflammatory disease of 
the digestive tract with systemic manifestations. Etiology 
is unknown, even if immunological, genetic and environ-
mental factors are involved. The majority of CD patients 
require surgery during their lifetime due to progressive 
bowel damage, but, even when all macroscopic lesions 
have been removed by surgery, the disease recurs in most 
cases. Postoperative management represents therefore 
a crucial mean for preventing recurrence. Several drugs 
and approaches have been proposed to achieve this aim. 
Endoscopic inspection of the ileocolic anastomosis within 
1 year from surgery is widely encouraged, given that en-
doscopic recurrence is one of the greatest predictors for 
clinical recurrence. A strategy should be planned only af-
ter stratifying patients according to their individual risk of 
recurrence, avoiding unnecessary therapies when possible 
benefits are reduced, and selecting high-risk patients for 
more aggressive intervention. 
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INTRODUCTION
Crohn’s disease (CD) is a chronic inflammatory disease of  
the digestive tract with associated several systemic manifes-
tations. Etiology of  CD seems to be multifactorial, which 
results from an interaction of  genetic susceptibility, immu-
nological dysregulation of  the mucosal immune system, gut 
microflora and environmental factors, but the final cause 
remains still unknown. Pathologically, CD is characterized 
by non-caseating granulomas and transmural inflammation, 
which can affect all the digestive tract from the mouth to the 
anus[1]. The most commonly affected sites are the ileum and 
ascending colon and the disease recurs in most cases after 
surgical resection of  macroscopically affected segments[1]. 
For this reason, almost all studies on postoperative recur-
rence are primarily focused on ileocolic disease. CD patients 
have a high likelihood of  undergoing repeated surgery for 
disease recurrence during their lifetime, with risk for short 
bowel syndrome: surgery in these patients is as conserva-
tive as possible in order to reduce this risk. Two distinct 
approaches are possible in clinical practice for postopera-
tive CD management: starting prophylactic medical therapy 
after surgery, which aims to avoid or postpone recurrence; 
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or waiting for endoscopic recurrence, and eventually start-
ing or adapting medical therapy before the patient becomes 
symptomatic. Both these strategies are rational and can be 
indicated in specific situations. Recurrence risk assessment 
after surgery is critical for correct decision making about 
medical prophylaxis and surveillance, and has to consider 
many different variables. Regueiro et al[2] have considered 
three grades of  recurrence risk: (1) very low, defined as long-
standing, first surgery, short stricture; (2) low-moderate, i.e. 
< 10-year-long history of  CD, presence of  a long stricture 
or any case of  inflammatory CD; and (3) high risk, defined 
as presence of  penetrating disease or patients with repeated 
intestinal resection (more than twice). Those patients may 
require a more aggressive approach[2]. This review provides 
an overview on this relevant and debated clinical topic. 
NATURAL HISTORY
Schofield introduced the definition of  “natural history” 
for ulcerative colitis first and later for regional enteritis[3]. 
The natural history of  CD is characterized by the pro-
gression of  bowel injury, which leads to surgery in up to 
80% of  patients during their lifetime[4]. Surgery in CD is 
not curative, even when all of  the macroscopic disease 
has been removed. Disease recurrence typically presents 
at an anastomotic site, mostly in the preterminal ileum in 
patients with previous ileal involvement[4]. Endoscopic 
surveillance programs for operated CD patients has led 
to identification of  endoscopic lesions (endoscopic re-
currence) that, in most cases, precede clinical symptoms 
(clinical recurrence). Clinical recurrence rates and reop-
eration rates increase over the years: about 80% of  pa-
tients will experience clinical recurrence within 20 years 
from surgery, and about 50% will undergo repeated sur-
gery during the same time in most series[4,5]. 
Regarding location, CD tends to be stable, since only 
about 6.5% of  the patients will experience a change of  
site in disease involvement over time[4]. Henriksen has 
investigated the changes in disease location in the Inflam-
matory Bowel South-Eastern Norway (IBSEN) popula-
tion-based study. Of  200 CD patients, only 14% changed 
affected site after 5 years[6].
It has to be underlined that biological therapies are 
relatively new in the management of  CD, and most of  
the studies on CD natural history refer to an era when 
the efficacy of  medication was lower compared to the 
present. Anti-tumor necrosis factor (TNF)-α antibodies 
like infliximab and adalimumab show strong efficacy in 
inducing mucosal healing: they could possibly modify 
the natural history of  the disease, but data on reduction 
of  the need for repeated surgery in the long-term are 
still not available. Data from clinical trials in inflammato-
ry bowel diseases (IBD) patients treated by anti TNF-α 
show that scheduled therapy significantly reduces the 
risk of  hospitalization and surgery related to CD up to 
55 mo on average[7,8]. There is then a reasonable perspec-
tive that scheduled therapy by infliximab or adalimumab 
might prevent or delay postoperative recurrence in high-
risk patients, with a significant change in the natural his-
tory of  the disease, although further large prospective 
studies focused on this topic are needed. 
Today, surgery remains part of  the clinical history 
of  CD patients[9,10]. In recent years, laparoscopic surgery 
is gaining a place in the surgical treatment of  CD, espe-
cially for ileocecal disease[4]. 
The assessment of  activity, severity and complications 
of  CD that may require surgical procedures remains a 
big challenge for physicians. Different kinds of  objective 
measures of  those parameters are available, but none of  
them is comprehensive for all aspects of  the disease. The 
Crohn’s disease activity index (CDAI)[11] and the Harvey-
Bradshaw index[12] are commonly used to assess the activ-
ity and severity of  the disease, but they can be affected by 
other non-CD gastrointestinal or extraintestinal disorders 
that may affect the correct evaluation of  the disease. 
These scores do not include the endoscopic features of  
the disease that can be measured using two other different 
scores: the Crohn’s Disease Endoscopic Index of  Sever-
ity[13] and the Simplified Endoscopic Score-Crohn’s Dis-
ease[14]. Other methods to assess disease activity include 
the level of  fecal markers, such as fecal calprotectin, fecal 
lactoferrin and polymorphonuclear neutrophil elastase, 
which are produced in the course of  bowel inflammation, 
and that can be detected in fecal samples. They have been 
shown to be more sensitive, specific and accurate than 
C-reactive protein in differentiating active from inactive 
disease, and to distinguish between CD-related symptoms 
and irritable bowel syndrome[15]. These non-invasive bio-
markers can also be used in the postoperative follow-up in 
order to distinguish bowel symptoms related to mechani-
cal causes (such as shortening of  the small bowel, colonic 
resection, bile salt diarrhea) from a clinical recurrence of  
CD. None of  these tools is comprehensive for all aspects 
of  CD; therefore, a new global score that considers clini-
cal, endoscopic, radiological parameters and surgical histo-
ry to assess the disease activity, severity and organ damage 
is urgently needed. 
 
CD RECURRENCE 
Definition
Recurrence is defined as reappearance of  lesions after 
complete surgical resection[16]. Recurrence can be assessed 
by endoscopy, radiology or surgery. Clinical recurrence 
is defined as the appearance, after complete resection of  
macroscopic disease, of  CD symptoms, which confirms 
recurrence of  the lesions[16]. This confirmation is impor-
tant because postoperative recurrence-like symptoms may 
be due to causes other than CD, such as motility distur-
bances or bile malabsorption. 
Endoscopic assessment 
The severity of  recurrence assessed by endoscopy is the 
best predictor of  clinical outcome in postoperative CD[17-21]. 
In order to correlate the endoscopic findings with the 
risk of  clinical recurrence, Rutgeerts has validated an en-
doscopic scoring system to be assessed at the first ileoco-
lonoscopy, 6-12 mo after surgery: it divides patients into 
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in non-smokers (P < 0.04)[28]. No differences were noted 
between ex-smokers and non-smokers[28]. 
Data about sex, age at onset of  the disease, duration 
of  the disease, resection margins, type of  surgery are 
discordant and inconclusive[27].
POSTOPERATIVE MANAGEMENT STRAT-
EGIES
General management
Postoperative management of  CD represents a hard chal-
lenge. Stratifying patients according to their risk is essential: 
not all the patients benefit from maintenance therapy, and a 
patient at high risk of  recurrence requires a different, stron-
ger therapy than others. Cigarette smoking is consistently 
correlated with CD recurrence and, among the known relat-
ed risk factors, it is the only potentially modifiable factor[29]. 
Therefore, as a first step for preventing recurrence, it should 
be stressed to every patient the importance to stop smoking 
after surgery for CD[29]. Smoking cessation decreases risk to 
the level of  that of  non-smokers[28].
Drug prophylaxis of recurrence
Prophylactic drugs have considerable costs and risks, 
with limited efficacy[4]. It has to be underlined that there 
is currently no evidence that, in terms of  reduction of  
hospitalization or need for surgery, prophylactic therapy 
gives any advantage over a strategy of  surveillance with 
prompt treatment of  recurrence[4]. An overview of  the 
most important drugs used to prevent recurrence fol-
lows. 
5-Aminosalicylic acid: 5-Aminosalicylic acid (5-ASA) 
has been extensively studied in postoperative manage-
ment of  CD. Lochs et al[30] and Florent et al[31] have treated 
patients with 5-ASA (mesalazine 4 g/d) or placebo for 
> 18 mo postoperatively, and have shown that clinical 
recurrence rates are lower in the 5-ASA group (24.5% vs 
31.4%), although the difference was not statistically signif-
icant. In a study by Florent et al, mesalazine (2.4 g/d) did 
not significantly reduce endoscopic recurrence rates at 12 
wk (50% vs 63%)[27]. Ewe et al[32] have demonstrated that 
sulfasalazine (3 g/d) significantly reduces clinical recur-
rence rates at 1 year (16% vs 28%, P < 0.01), with effects 
maintained at 2 years. Endoscopic recurrence has been 
shown to occur more rarely after 12 mo mesalazine treat-
ment (3 g/d); however the clinical recurrence rates were 
similar in the two groups[33]. In a recent double-blind trial, 
two groups were randomized to receive 4 g or 2.4 g/d of  
mesalazine at 2 wk after surgery. At 12 mo, endoscopic 
recurrence was higher in the second group, although clini-
cal recurrence rates were similar in both groups[12]. The 
current evidence seems to indicate that 5-ASA is generally 
safe in postoperative CD prophylaxis, even if  it seems to 
provide, at best, only a small reduction in clinical and en-
doscopic recurrence[1].
Antibiotics: Two randomized clinical trials[34,35] have 
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five groups (i0-i4, see Table 1)[17], according to the severity 
of  endoscopic lesions; in the i0-i1 group, there is < 5% 
recurrence at 3 years; in i2, about 15%; in i3, 40%; and i4, 
> 90%[17]. The most common endoscopic lesions are aph-
thous ulcerations that are located in the neoterminal ileum 
near to the anastomotic area[17]. In the absence of  treat-
ment, such lesions can evolve into large ulcerations or tight 
strictures: Rutgeerts has reported that only 20% of  these 
patients become clinically symptomatic within 1 year after 
surgery[17]. Symptoms develop only after a lesion has been 
established, and it is not uncommon to find endoscopic 
severe lesions in an asymptomatic patient. Clinical scoring 
systems such as the CDAI may therefore be of  little help 
in identifying patients with postoperative recurrence[22].
Risk factors
Most patients experience disease recurrence over time, but 
long-term medical strategies for prevention of  recurrence 
can carry various risks: risk-benefit analysis should be in-
dividualized to each patient. Identification of  risk factors 
for CD recurrence is therefore extremely important in 
order to identify high-risk patients, who are more likely 
to benefit from an aggressive therapeutic strategy. 
Several factors have been studied as possible contribu-
tors to CD recurrence, including age, sex, cigarette smok-
ing, age at onset of  disease, duration of  disease, anatom-
ical site, extent and severity of  disease, previous surgery, 
and disease phenotype, disease-free margins, anastomotic 
technique, blood transfusion, and occurrence of  compli-
cations. 
Among these many factors, the following have been 
shown to predict early recurrence in the majority of  studies: 
smoking[23], prior intestinal surgery (including appendecto-
my)[24], penetrating disease behavior[25], perianal involvement, 
and extended small bowel resection (> 100 cm)[26]. Absence 
of  prophylactic therapy is associated with early relapse (de-
fined as a flare of  symptoms)[27]. 
Reese et al[28] in a recent meta-analysis have reported 
that clinical relapse occurred in 58.3% of  smoking pa-
tients, compared with 39% of  non-smokers (P < 0.005). 
The 5-year reoperation rate was higher among smokers, 
but not significantly (34.2% vs 31.1%); however, this 
difference becomes significant when considering the 
10-year reoperation rates: 55.5% in smokers and 17.5% 
Table 1  Endoscopic recurrence score as reported by Rutg-
eerts et al [17]
Endoscopic 
score Definition
i0 No lesions
i1 ≤ 5 aphthous lesions
i2 > 5 aphthous lesions with normal mucosa between the le-
sions, or skip areas of larger lesions, or lesions confined to 
the ileocolic anastomosis
i3 Diffuse aphthous ileitis with diffusely inflamed mucosa
i4 Diffuse inflammation with already large ulcers, nodules, 
and/or narrowing
Remission: Endoscopic score i0 or i1; Recurrence: Endoscopic score of i2-i4.
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evaluated antibiotic therapy in the prevention of  CD re-
currence after surgery. In the first study, patients treated 
with metronidazole (20 mg/kg per day, for 3 mo after 
surgery) had a reduced incidence of  severe endoscopic 
recurrence after a follow-up of  1 year (4% vs 25%), but 
experienced a three times higher incidence of  side ef-
fects than the placebo group (23.3% vs 6.7%)[36]. Similar 
results were obtained by another study by the same 
group on another nitroimidazole antibiotic, ornidazole 
(1 g/d), administered for 1 year: recurrence rates were 
reduced at 1 year, but not maintained at 2 and 3 years. 
The therapy in these studies was not well tolerated. Ni-
troimidazole antibiotics have shown efficacy in reducing 
severe endoscopic recurrence in the short- and medium-
term and can be eventually associated with other treat-
ments in the first postoperative period[1]. The possible 
use of  other more tolerable antibiotics such as rifaximin 
or ciprofloxacin has still to be evaluated. 
Budesonide: Two large randomized clinical trials have 
found that oral budesonide is ineffective in reducing post-
operative recurrence rates after surgery for CD[37]. Ewe et al[32] 
have found that endoscopic and clinical recurrences after 
1 year were not significantly different when comparing 
budesonide to placebo treatment; Hellers et al[38] have not 
found differences between the two groups at 3 and 12 mo 
regarding endoscopic recurrence rates.
Immunomodulators: The thiopurines azathioprine 
(AZA)/6-mercaptopurine (6-MP) have proven efficacy 
and are widely recommended for postoperative prophy-
laxis of  recurrence after surgery for CD. Ardizzone et al 
have demonstrated that patients after surgical resection 
benefit more from AZA than mesalazine for prevention 
of  clinical recurrence, despite the side effects experi-
enced by patients in the AZA group (22% vs 8% com-
pared to the mesalazine group)[1]. Hanauer et al[36] have 
found that clinical recurrence at 2 years was 50% in the 
6-MP group, 58% in the mesalazine, and 77% in the pla-
cebo group. In this study, only 69% of  patients assigned 
to 6-MP was able to complete the treatment, because 
of  the significant side effects. A recent meta-analysis 
of  four controlled studies of  AZA for recurrence pro-
hylaxis has demonstrated its efficacy for reducing the 
incidence of  overall recurrence at 12 mo. On the other 
hand, the rate of  adverse events leading to therapy with-
drawal was higher in the AZA group than in the control 
groups[39]. Thiopurines have been shown to be more 
effective than mesalazine for prevention of  postopera-
tive recurrence, despite the higher rate of  side effects 
reported[1]. 
Anti-TNF agents: There is only one randomized, 
double-blind, placebo-controlled trial that has assessed 
the efficacy of  infliximab for reducing postoperative re-
currence rates after ileocolic resection[2]: 24 patients were 
randomized to receive 5 mg/kg infliximab with a standard 
three-dose induction and a maintenance dose once every 
8 wk, for 1 year, versus placebo. In the infliximab group, 
9.1% developed endoscopic recurrence compared with 
84.6% in the placebo group (P = 0.0006). Infliximab pa-
tients experienced a significantly lower risk of  endoscopic, 
histological and clinical recurrence at 1 year[2]. No data are 
available about other anti-TNF agents for preventing CD 
recurrence after surgery. 
 
Other therapies
Different types of  probiotics have been evaluated, but 
none of  them has showed a significant effect over placebo 
in preventing recurrence. There is no evidence for the use 
of  other agents such as synbiotics or interleukin-10 for 
preventing CD recurrence after surgery[40-44]. 
Endoscopic surveillance strategy
Surgery for CD treats complications such as strictures, 
abscesses or fistulae, but it cannot interrupt the course of  
the disease. Postoperative recurrence rate in absence of  
treatment reaches 65%-90% within 12 mo and 80%-100% 
within 3 years from surgery [27], with an increase of  
22%-25% per year[19,45]. Moreover, about 50% of  the pa-
tients will need reoperation within 10 years after the first 
bowel resection[9,16,24-26,46,47]. It is therefore important to plan 
a surveillance of  the patient after having assessed their risk 
of  recurrence and chosen the most indicated treatment. 
The CDAI can be used to assume the possible activ-
ity of  the disease, but in postoperative settings it does not 
reach a sufficient sensitivity to predict disease recurrence 
accurately: patients with a high CDAI may be completely 
asymptomatic[22]. Fecal markers can play a role, but their use 
for this particular indication needs further investigation.
Rutgeerts et al[47] have developed a validated endo-
scopic score to measure the postoperative recurrence and 
stratify patients, according to their endoscopic findings, in 
five categories, already described (see Table 1 for details). 
The severity of  endoscopic lesions correlates with the risk 
of  disease progression. Endoscopic signs of  recurrence 
do appear before symptomatic disease, which allows early 
treatment that may be effective in modifying the natural 
course of  the disease, preventing clinical recurrence and 
possibly, the need for new surgery. 
Patients presenting with no or minimal endoscopic 
lesions (endoscopic score i0-2) may not benefit from 
therapy; on the contrary, severe endoscopic recurrence 
(endoscopic score i3-4) should promote aggressive thera-
py. Based on correlation data between endoscopic lesions 
and clinical recurrence, and on data about risk factors for 
postoperative CD recurrence, patients can be considered 
at low risk if  their disease is long-standing, mainly fibroste-
notic, and involves a limited bowel segment; on the other 
hand, all other patients, especially active smokers, with 
prior intestinal surgery, perianal disease, perforating and in-
flammatory disease, who have undergone extensive bowel 
resection should be considered at high risk for recurrence. 
It can be a rational strategy to wait to treat low-risk pa-
tients until performing the first ileocolonoscopy, 6 mo to 
1 year postoperatively, and reserving the immediate start 
of  postoperative prophylactic therapy (with thiopurines 
or anti-TNF) for high-risk patients. For low-risk patients, 
if  there is endoscopic recurrence at ileocolonoscopy, im-
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munomodulatory or anti-TNF therapy could be started; 
if  negative, only a new endoscopic surveillance can be 
performed 1-3 years later. Further optimization or modi-
fication of  therapy could be performed according to the 
severity of  endoscopic lesions, repeating ileocolonoscopy 
after another 6-12 mo. For patients at high risk of  recur-
rence, thiopurines or anti-TNF treatment is recommended, 
starting a few weeks after surgery; if  endoscopic controls 
during surveillance reveal recurrence of  disease, it is pos-
sible to intensify the dose or switch to another agent[29]. 
Surgical strictureplasty represents a valid treatment for 
most patients with small bowel strictures, while its role in 
duodenal and colonic disease remains debated[48]. A recent 
meta-analysis by Yamamoto et al[48] has shown that younger 
age, short duration of  the disease, and short interval from 
previous resection can increase the risk of  recurrence. Dif-
ferently form what previously reported[49], the most recent 
evidence has shown that the number of  strictures and 
strictureplasties do not affect the risk of  recurrence[48]. Ex-
cept for the duodenum and the last ileal loop, small bowel 
is difficult to be explored endoscopically; therefore, data 
regarding the CD recurrence are focused on ileocecal re-
section, and there is no evidence that medical management 
or timeline for surveillance after strictureplasty is different 
than in patients undergoing ileocecal resection. 
CONCLUSION
CD recurrence after surgery is very frequent. Identification 
of  risk factors for recurrence is extremely important in 
order to stratify patients according to their risk, identifying 
those who can benefit from an aggressive medication regi-
men, possibly modifying the natural course of  the disease. 
If  postoperative prophylaxis of  recurrence is indicated, 
then thiopurines (eventually with metronidazole) and anti-
TNF agents are the most effective choices. Ileocolonos-
copy within 1 year of  surgery, regardless of  the eventual 
postoperative treatment, is widely recognized as the best 
tool for early detection of  CD recurrence, allowing tailor-
ing the appropriate therapy to the individual patient. A 
summary of  the suggested management of  postoperative 
recurrence is shown in Figure 1. Cooperation between gas-
troenterologists, endoscopists and surgeons is desirable in 
order to assess the risk of  recurrence, to plan postoperative 
surveillance (not limited to symptomatic flares), and to of-
fer the most appropriate treatment strategy to the patient. 
Which approach would be better for treating and prevent-
ing postoperative recurrence of  CD remains debatable.
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